Abcam’s CEO wins Mediscience award

  • Award recognizes the biggest contribution to the Mediscience sector

Cambridge UK, June 20, 2014: Abcam plc., a leading provider of innovative protein research tools and services, is pleased to announce that its CEO, Dr Jonathan Milner, has won the European Mediscience award for the ‘Most significant contribution to the Mediscience sector’.

Picture shows, left to right: Erik Manting, Executive Director, Life Sciences and Health, Kempen & Co; Dr. Brian White, Shore Capital; Jonathan Milner (winner); and Louise Minchin, awards presenter.

The European Mediscience Awards is the largest annual gathering of private and publicly quoted healthcare, biotech and life sciences companies in Europe. The awards celebrate the best breakthroughs, technology and significant contributions from individuals and companies in the Mediscience sector.

Jonathan’s committment to the Mediscience sector is driven by a passion for a better understanding of human health and disease. Starting out as a breast cancer researcher at the University of Cambridge, and frustrated by a lack of high-quality antibodies in the market, Jonathan founded Abcam in 1998. Dubbed the ‘Amazon of Antibodies’ for its unique data-rich products, the Company has evolved from humble beginnings and is now a market leader providing innovative products such as RabMAb® primaries and a range of other life science products to help advance protein research globally.

In recent years, Jonathan has been involved with several exciting research initiatives and is the principle investor in Horizon Discovery and co-founder of Axol Bioscience.

“I’m delighted to have won the award for the most significant contribution to the Mediscience sector. At Abcam, we’re passionate about accelerating the pace of scientific discoveries to better understand human health and disease. I would like to thank our employees who are dedicated to our mission of enabling scientists to discover more ”

– Dr Jonathan Milner, CEO, Abcam